98 results about "Bacterial enterotoxins" patented technology

Gene expression profiling and hierarchial clustering analysis readily distinguish normal ovarian epithelial cells from primary ovarian serous papillary carcinomas. Laminin, tumor-associated calcium signal transducer 1 and 2 (TROP-1/Ep-CAM; TROP-2), claudin 3, claudin 4, ladinin 1, S100A2, SERPIN2 (PAI-2), CD24, lipocalin 2, osteopontin, kallikrein 6 (protease M), kallikrein 10, matriptase and stratifin were found among the most highly overexpressed genes in ovarian serous papillary carcinomas, whereas transforming growth factor beta receptor III, platelet-derived growth factor receptor alpha, SEMACAP3, ras homolog gene family, member I (ARHI), thrombospondin 2 and disabled-2/differentially expressed in ovarian carcinoma 2 (Dab2/DOC2) were significantly down-regulated. Therapeutic strategy targeting TROP-1/Ep-CAM by monoclonal chimeric/humanized antibodies may be beneficial in patients harboring chemotherapy-resistant ovarian serous papillary carcinomas. Claudin-3 and claudin-4 being receptors for Clostridium Perfringens enterotoxin, this toxin may be used as a novel therapeutic agent to treat ovarian serous papillary tumors.

The invention discloses high levels of receptors for Clostridium perfringens enterotoxin (CPE) have been found in ovarian cancer and uterine cancer tissue samples. In addition, successful in vivo treatment of a mouse model of ovarian cancer with intraperitoneal injection of CPE is disclosed. High levels of Ep-CAM protein is also disclosed in ovarian cancer tissue samples. Thus, the invention provides a method of treating ovarian cancer and uterine cancer by administering CPE. The invention also provides a method of treating cancer in a mammal involving intraperitoneal administration of CPE, where at least some cancerous cells are located in or adjacent to the peritoneal cavity of the mammal. The invention also provides a method of treating ovarian cancer involving administering an anti-Ep-CAM antibody. The invention also provides a method of treating cancers expressing claudin-3 or claudin-4 by administering an antibody against claudin-3 and/or an antibody against claudin-4. The invention also provides a method of protecting a mammal from CPE toxicity involving administering a protective agent that binds to claudin-3 and/or claudin-4 and inhibits CPE binding to claudin-3 and/or claudin-4.

Methods of diagnosis, prognosis, and treatment of breast cancer, and of metastatic brain cancer, are provided The diagnostic and prognostic methods involve the immunohistochemical detection of the level of expression of the proteins claudin 1, 3, 4, and 7 in tissue or cell samples. Claudins 1 and 7 are underexpressed in the majority of breast cancers, and claudins 3 and 4 are overexpressed. The methods of treatment involve the use of Clostridium perfringens enterotoxin (or a variant thereof) to lyse metastatic cancer cells in the brain and bone that overexpress claudins 3 and 4.

The invention provides strains of bacteria, especially enterotoxigenic E. coli, attenuated by mutations in the genes encoding enterotoxins (LT, ST, EAST1) and optionally further attenuated by deletion of additional chromosomal genes. In addition the invention provides strains of attenuated bacteria expressing immunogenic but non-toxic variants of one or more of these enterotoxins. These bacteria are useful as a vaccine against diarrhoeal disease.

The present invention is directed to an enterotoxin adsorbent comprising a compound having a log P (P denotes a partition coefficient in an octanol-water system) value of not less than 2.50 as immobilized on a water-insoluble carrier.

The inventive subject matter relates to an immunogenic composition composed of a chimeric molecule including a conformationally stable adhesin from Escherichia coli fused to a bacterial toxin A subunit, such as cholera toxin A subunit or heat-labile Escherichia coli toxin A subunit. The invention also relates to the adhesin-toxin chimera noncovalently associated with a toxin B subunit of the same or different species as the A subunit. The invention also relates to a method of utilizing an adhesin/toxin fusion composition to elicit an immune response.

The invention provides an effective and environmentally friendly antibody protective agent and the methods of using it in immunological detection. The antibody protective agent helps antibody to maintain relatively high immunological activity at room temperature. Working electrodes coated with antibodies and the antibody protective agent are installed in immunological detection devices to enhance stability and accuracy of immunological detection. The antibody protective agent is effectively used in the detection of a variety of toxins, for example, aflatoxin, staphylococcal enterotoxin, algae toxin, and vomitoxin.

The invention discloses a staphylococcal enterotoxin gene engineering reshaped antibody and its preparation method and use. The staphylococcal enterotoxin gene engineering reshaped antibody has an amino acid sequence shown in the formula of SEQ ID No.1 in the sequence table. Through construction of light and heavy chain eukaryotic co-expression vectors of the staphylococcal enterotoxin monoclonal antibody, a high-efficiency expression and stable-secretion mammalian cell line and the gene engineering reshaped antibody having high singularity and strong affinity are obtained. The staphylococcal enterotoxin gene engineering reshaped antibody can be used in staphylococcal enterotoxin detection, cell indirect immunofluorescence detection and flow cytometry detection.

The invention discloses a gene recombinant vaccine for preventing enterovirus 71 (EV71) infection and a preparation method thereof. The inflection comprises multiple diseases related with the nervous system such as hand-foot-and-mouth disease, paralytic diseases of sterile meningitis, cephalitis and poliomyelitis and the like. Escherichia coli labile enterotoxin B subunit (LTB) is used as an immunological enhancement adjuvant, two fragments of linear neutralizing epitope SP55 and SP70 in EV71 virus coat protein VP1 are used as antigens, prokaryotic expression plasmids of LTB-SP55-SP70 fusion genes are constructed by using gene engineering technology, the plasmids are expressed in escherichia coli, and a recombinant expression product is purified for preparing the EV71 virus gene engineering vaccine.

An application of staphylococcus aureus enterotoxin in preparing the medicines for preventing and treating AIDS is disclosed. Said enterotoxin may be SEA, SEB, SEC1, SEC2, and SED. Its advantages are low dosage and high curative effect.

The invention relates to a protein G staphylococcus aureus enterotoxin kit and a preparation method thereof. Protein G is adopted to preprocess an enzyme labeling plate, and quick and accurate detection on staphylococcus aureus enterotoxin A/B is realized by combining with an ELISA double-antibody sandwich method. The kit consists of the 96-hole enzyme labeling plate, a staphylococcus aureus enterotoxin A-resistant protein G recombinant protein monoclonal antibody, a staphylococcus aureus enterotoxin B-resistant monoclonal antibody, a staphylococcus aureus enterotoxin antibody enzyme labeling object containing a horseradish peroxidase label, a sample diluent, a cleaning solution and a stop buffer. The protein G staphylococcus aureus enterotoxin kit can quickly and effectively detect the residual level of tony red in a to-be-detected sample, and also has the characteristics of simple operation, good specificity, high sensitivity, and the like.

The invention discloses a colloidal gold immuno-chromatography test paper strip used for detecting escherichia coil F5 pilus and a preparation method thereof, which relate to a test paper strip for detecting escherichia coil pilus and a preparation method thereof. The invention provides the colloidal gold immuno-chromatography test paper strip used for detecting escherichia coil F5 pilus and the preparation method thereof. The test paper strip consists of a PVC back lining, a sample pad, a combination pad, a cellulose nitrate membrane and a water absorbent pad. The preparation method comprises the following steps of: preparing an immunogen; coating an anti-F5 pilus polyclonal antibody and a sheep anti-mouse IgG on the cellulose nitrate membrane; preparing an anti-F5 pilus monoclonal antibody; coating the anti-F5 pilus monoclonal antibody and a colloidal gold marker on the combination pad; and finally, continuously adhering the sample pad, the combination pad, the cellulose nitrate membrane and the water absorbent pad on the PVC back lining in turn, and cutting the PVC back lining into the test paper strip. The colloidal gold immuno-chromatography test paper strip has high specificity, stability and sensibility, can be used for identifying enterotoxigenic escherichia coil F5 pilus, has an intuitive result, and is convenient to be conserved.

The invention discloses a weight losing prescription, and relates to a Chinese medicinal formula. The weight losing prescription is prepared from the following Chinese medicinal herbs by weight: 40 grams of oriental wormwood, 20 grams of fleece-flower root, 30 grams of cherokee rose fruit, 30 grams of many-flower solomonseal rhizome, 15 grams of raw hawthorn, 20 grams of root of red-rooted salvia, 10 grams of rhubarb, 5 grams of pseudo-ginseng powder, 20 grams of kudzuvine root, 30 grams of medlar, and 15 grams of white atractylodes rhizome. A preparation method for the prescription comprises the following step of: decocting the Chinese medicinal herbs by adding water in a weight ratio, wherein the decoction is taken twice every day. The prescription can clear enterotoxin, is naturally mild, does not have side effect, and has a good weight losing effect.

The invention aims to provide a duck Tembusu virus gene engineering subunit vaccine which is prepared by the following steps: screening to obtain duck Tembusu virus E protein with Domain III structure field of dominant antigen epitope, constituting a novel fusion protein LTB-Es from Lingker and enterotoxin LTB, and preparing the duck Tembusu virus gene engineering subunit vaccine by using the fusion protein as the antigen. The amino acid sequence of the coding protein of the duck Tembusu virus novel fusion protein LTB-Es is SEQ ID NO:1, and one of the nucleotide sequences is SEQ ID NO:2. The prokaryotic expression vector is utilized to construct the Escherichia coli BL21(DE3) host bacterium capable of expressing the duck Tembusu virus novel fusion protein LTB-Es. The gene engineering subunit vaccine prepared from the purified recombinant expressed protein can enable the immunized duck group to obtain immunoprotection.

A reagent bar used for quickly detecting staphylococcus enterotoxin consists of reagent, reagent bar and micro-scale pipet. It is featured as using cell clasmatosis solution as reagent and carrying 20 micron L of specific single clone antibody of anti-staphylococcus enterotoxin, collaurum labeled single clone antibody of anti-staphylococcus enterotoxin, collaurum labeled quality control antigen and antibody of relevant antigen on reagent bar.

The invention discloses a magnetic particle chemiluminescence assay kit and a method for detecting SEA, and belongs to the technical field of food safety detection. The method is a magnetic particle chemiluminescence assay method for fast detecting SEA in foods and preparations. The method comprises the following steps of diluting a standard substance, adding a marker into the dilute standard substance, carrying out uniform mixing, warm bath, sedimentation and washing, adding a luminous substrate into the mixture, determining chemiluminescence intensity, drawing a standard curve, wherein an OD value of a detected sample is in the range of the standard curve. The magnetic particle chemiluminescence assay kit has the advantages of simple operation, fast speed, high sensitivity, strong singularity and low cost.

The invention relates to compound yolk antibody powder, a preparation method and a preparation thereof, wherein the compound yolk antibody powder contains an anti-parvovirus antibody, an anti-coronavirus antibody, an anti-rotavirus antibody and an anti-enterotoxin type Escherichia coli tetravalent antibody. According to the present invention, the compound yolk antibody powder can prevent and treat the bacterial diarrhea of dogs and cats, can replace the use of antibiotics to reduce the morbidity and the mortality of dogs and cats, and further contains lecithin so as to promote the skin brightening and the hair brightening of cats and dogs and reduce the occurrence of skin diseases.

The invention discloses a lactobacillus capable of adsorbing or degrading enterotoxin and an application thereof. The preservation number of the lactobacillus is CCTCC No: M2015128. The lactobacillus can adsorb or degrade enterotoxin and has the good effects of resisting acid, cholate, artificial gastric juice and artificial intestinal juice. The lactobacillus is specifically characterized in that the enterotoxin can be adsorbed or degraded, and good enterotoxin removal capacity is achieved; growth of common pathogenic bacteria can be restrained; the lactobacillus can resist acid and cholate and can survive in the digestive tract. In specific application, a method includes the step that freeze-dried bacterial powder is dissolved in water at normal temperature to be taken orally or is directly added according to a certain proportion to make functional food or healthcare products. The lactobacillus is screened from multiple lactobacilli, has the high enterotoxin removal capacity and good performance, and can be used for human body healthcare.

The invention provides a method for constructing a K88ac<+> enterotoxigenic escherichia coli attenuated virus strain. The method includes the following steps that 1, K88ac<+> enterotoxigenic escherichia coli enterotoxin genes are subjected to traceless point mutation, wherein TCT on the LT I gene of K88ac<+> enterotoxigenic escherichia coli without antibiotics resistance genes is mutated into AAA, and correspondingly-encoded No. 63 serine is mutated into lysine (K); 2, the K88ac<+> enterotoxigenic escherichia coli enterotoxin genes are knocked out, wherein on the basis of the first step, the ST II genes in the K88ac<+> enterotoxigenic escherichia coli are knocked out, and therefore the aim of attenuating the K88ac<+> enterotoxigenic escherichia coili is achieved accordingly. The attenuated virus strain constructed with the method is high in adhesivity and long in in-vivo planting time, infection of the pathopoiesia stain can be prevented, and the method can be used for biological preventing of colibacillosis caused by K88ac<+> ETEC.

A detoxified recombinant E. coli heat-labile enterotoxin mutant, LTS61K, is employed as a carrier protein to conjugate polysaccharide. The LTS61K contains a mutated mature sub-unit A (LTA) that includes lysine at amino acid position 61 and a wild-type mature sub-unit B (LTB). Various types of bacterial capsular polysaccharide antigens were chemically conjugated with the LTS61K protein by a reductive amination reaction. The conjugated polysaccharide-LTS61K products were physically, chemically and biochemically identified as soluble form. Rabbits were immunized intramuscularly to determine the immunogenicity of conjugated vaccines by ELISA to detect anti- polysaccharide antigen IgG titers and serum bactericidal assay thereby determining the functional activity of the antibodies.; Study results show that conjugated polysaccharide-LTS61K vaccines induce higher polysaccharide-specific IgG titers and greater bactericidal activity in sera than that of polysaccharide alone or polysaccharide mixed with LTS61K. The presence of anti-LTS61K serum IgG antibody alleviates travel diarrhea caused by E. coli (ETEC enterotoxigenic E. coli).